1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
3SBio Inc.

3SBio Inc.

TRSBF
3SBio Inc.US flagOther OTC
2.15
USD
- -
- -
5.38BMarket Cap
3SBio Inc.
TRSBF
(Other OTC)

Recent

price

2.15

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.58
0.74
1.11
1.47
1.8
2.1
2.2
2.51
2.81
3.2
3.76
7.32
Revenue per Share
0.15
0.23
0.28
0.37
0.5
0.38
0.33
0.65
0.78
0.64
0.86
3.51
Basic EPS, GAAP
0.19
0.16
0.21
0.33
0.28
0.55
0.14
0.17
0.47
0.57
0.92
3.77
Free Cash Flow per Basic Share
0.34
- -
- -
- -
0.06
0.01
- -
- -
0.17
0.09
0.23
0.23
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
3.21
3.76
4.45
7.57
Book Value per Share
0.16
2.03
0.14
0.57
0.99
1.6
2.87
3.53
3.95
4.41
4.99
10.13
Tangible Book Value per Share
1,940
2,255
2,524
2,535
2,541
2,535
2,535
2,543
2,444
2,439
2,424
2,419
Basic Weighted Avg Shares
1,131
1,673
2,797
3,734
4,584
5,318
5,588
6,382
6,866
7,816
9,108
17,696
Sales/Revenue/Turnover
31.27
27.6
32.74
31.88
29.53
24.28
27.98
29.48
30.14
31.45
29.99
60
Operating Margin (%)
33
77
161
244
322
334
361
329
370
335
395
530
Depreciation Expense
292
526
713
935
1,277
974
836
1,651
1,916
1,549
2,090
8,482
Net Income, GAAP
19.01
10.48
15.98
16.12
14.59
19.85
21.25
12.91
16.26
19.82
18.42
15.37
Effective Tax Rate (%)
25.8
31.45
25.47
25.05
27.86
18.31
14.96
25.87
27.9
19.82
22.95
47.93
Profit Margin (%)
-309
1,990
1,097
3,080
2,782
2,984
5,229
6,371
7,907
5,465
3,883
18,255
Working Capital
- -
- -
2,541
3,319
2,724
2,322
2,547
2,468
4,093
2,717
69
768
LT Debt
944
5,635
6,766
7,630
8,907
10,359
13,093
14,658
15,364
16,514
18,036
30,436
Total Equity
- -
10.83
9.66
9.06
9.46
8.13
8.42
9.8
9.28
9.53
10.36
32.75
Return on Invested Capital (%)
- -
105.28
44.9
26.82
33.92
29.58
21.76
33.4
20.23
10.75
12.68
38.61
Return on Capital (%)
- -
683,480.52
461,206.47
601,536.33
818,696.79
626,184.57
539,220
1,065,320.65
48.85
18.21
20.95
58.32
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.45%
20.45%
68.75%
Free Cash Flow
68.87%
115.25%
307.84%
Net Income, GAAP
50.05%
87.03%
305.78%
Sales/Revenue/Turnover
29.1%
29.29%
94.29%
Total Cash Common Dividend
- -
- -
0.85%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
7,816
2024
- -
- -
- -
- -
9,108
2025
- -
- -
- -
- -
17,696

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.64
2024
- -
- -
- -
- -
0.86
2025
- -
- -
- -
- -
3.51

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.09
2024
- -
- -
- -
- -
0.23
2025
- -
- -
- -
- -
0.23
Similar Companies
GenMont Biotech Incorporation (3164.TW)
Tyme Technologies, Inc. (TYME)
Dimerix Limited (DXB.AX)
TAO Synergies Inc. (TAOX)
Viva Biotech Holdings (1873.HK)
Intellipharmaceutics International Inc. (IPCIF)
Business
3SBio Inc. operates as a prominent biopharmaceutical company, engaged in the research, development, production, commercialization, and sale of a diverse portfolio of pharmaceutical products primarily within the People's Republic of China and extending to international markets. The company offers TPIAO, a recombinant human thrombopoietin injection, for managing chemotherapy-induced thrombopenia, immune thrombocytopenia, and pediatric immune thrombocytopenia. For autoimmune conditions such as rheumatoid arthritis, ankylosing spondylitis, and psoriasis, the company provides YISAIPU, a recombinant human tumor necrosis factor-alpha receptor II: IgG Fc fusion protein. Additionally, its product lineup includes recombinant human erythropoietins, EPIAO and SEPO, to address anemia linked with chronic kidney disease and chemotherapy, alongside reducing the need for allogeneic blood transfusions in surgical patients. In oncology, 3SBio markets Cipterbin, an anti-HER2 monoclonal antibody used in combination chemotherapy for HER2-positive metastatic breast cancer. A significant development in 2025 involved a global licensing agreement, excluding China, with Pfizer for SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently in clinical trials for non-small cell lung cancer, gynecological tumors, and metastatic colorectal cancer. Pfizer's deal included an upfront payment, potential milestone payments, and an equity investment, with an option for commercialization rights within China. The company also provides Mandi, a minoxidil-based solution for androgenetic alopecia and alopecia areata. Other therapeutic offerings include Remitch for hemodialysis pruritus and Xenopax for preventing acute rejection following renal transplants. Leveraging its integrated platform, which encompasses in-house research and development, clinical progression, and cGMP-compliant manufacturing capabilities across multiple sites in China and Italy, 3SBio is also involved in contract development and manufacturing services. The firm maintains strategic collaborations with various multinational pharmaceutical entities and actively pursues international expansion through licensing and partnerships. Established in 1993, the company maintains its headquarters in Shenyang, People's Republic of China.

Company News

APIChatGPT

  • defenseworld.net

    3SBio (TRSBF) Expected to Announce Earnings on Monday